IMR Press / FBL / Volume 13 / Issue 6 / DOI: 10.2741/2828

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Gene therapy in prostate cancer: past, present and future
Show Less
1 Division of Infectious Disease Control, International Center for Medical Research and Treatment, Kobe University School of Medicine, Japan
2 Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Japan
3 Laboratory of Cell and Gene Therapy, Institute for Advanced Medical Science, Hyogo College of Medicine, Japan

*Author to whom correspondence should be addressed.

 

Front. Biosci. (Landmark Ed) 2008, 13(6), 2115–2119; https://doi.org/10.2741/2828
Published: 1 January 2008
Abstract

The absence of effective therapies for hormone refractory prostate cancer establishes the need to develop novel therapeutic modality, such as a gene therapy, that can be applied either separately or in conjunction with current treatment modalities for the treatment of advanced prostate cancer. About 80 protocols for prostate cancer gene therapy have been practiced since 1994. The gene therapy modality is ideal for the treatment of prostate cancer. The disease progress can be precisely monitored by serum-PSA level, the local access is easy by ultra-sound guidance, and prostate as an accessory organ is highly immunogenic. Consequently, the number of prostate cancer gene therapy trials is increasing now. In this paper, we review the previous clinical trials of prostate cancer gene therapy in the chronologic order, and predict the future prospects.

Share
Back to top